The latest price target for Charles River (NYSE:CRL) was reported by Barclays on August 8, 2024. The analyst firm set a price target for $210.00 expecting CRL to rise to within 12 months (a possible 4.49% upside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for Charles River (NYSE:CRL) was provided by Barclays, and Charles River maintained their equal-weight rating.

The last upgrade for Charles River Laboratories International Inc happened on February 23, 2023 when Guggenheim raised their price target to $255. Guggenheim previously had a neutral for Charles River Laboratories International Inc.

The last downgrade for Charles River Laboratories International Inc happened on August 8, 2024 when JP Morgan changed their price target from $270 to $205 for Charles River Laboratories International Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Charles River, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Charles River was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.

While ratings are subjective and will change, the latest Charles River (CRL) rating was a maintained with a price target of $230.00 to $210.00. The current price Charles River (CRL) is trading at is $200.97, which is out of the analyst’s predicted range.